Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Shares Sold by Caxton Corp

Caxton Corp cut its stake in shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Free Report) by 60.6% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 2,015,157 shares of the company's stock after selling 3,098,191 shares during the period. Xeris Biopharma accounts for 41.1% of Caxton Corp's holdings, making the stock its largest position. Caxton Corp owned about 1.35% of Xeris Biopharma worth $6,831,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors also recently made changes to their positions in the company. NewEdge Advisors LLC acquired a new position in shares of Xeris Biopharma during the 4th quarter worth approximately $34,000. R Squared Ltd acquired a new stake in Xeris Biopharma during the fourth quarter worth approximately $42,000. Cibc World Markets Corp bought a new position in Xeris Biopharma during the 4th quarter worth $44,000. Raymond James Financial Inc. bought a new position in Xeris Biopharma during the 4th quarter worth $45,000. Finally, Aquatic Capital Management LLC acquired a new position in Xeris Biopharma in the 4th quarter valued at $50,000. Institutional investors own 42.75% of the company's stock.

Xeris Biopharma Stock Performance

Shares of XERS traded up $0.68 during mid-day trading on Thursday, reaching $5.16. The company had a trading volume of 5,208,857 shares, compared to its average volume of 1,931,760. The company's 50 day simple moving average is $4.64 and its 200 day simple moving average is $3.84. The company has a market capitalization of $806.95 million, a price-to-earnings ratio of -11.47 and a beta of 1.10. Xeris Biopharma Holdings, Inc. has a 1-year low of $1.72 and a 1-year high of $6.07.

Xeris Biopharma (NASDAQ:XERS - Get Free Report) last posted its earnings results on Thursday, May 8th. The company reported ($0.06) earnings per share for the quarter, topping analysts' consensus estimates of ($0.07) by $0.01. The company had revenue of $57.80 million for the quarter, compared to the consensus estimate of $57.61 million. As a group, equities analysts forecast that Xeris Biopharma Holdings, Inc. will post -0.41 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of brokerages recently commented on XERS. HC Wainwright restated a "buy" rating and issued a $8.00 price target (up previously from $6.60) on shares of Xeris Biopharma in a research report on Friday, March 7th. Craig Hallum raised their target price on shares of Xeris Biopharma from $5.00 to $6.50 and gave the company a "buy" rating in a report on Friday, March 7th. Leerink Partners upped their price target on shares of Xeris Biopharma from $5.00 to $6.00 and gave the stock an "outperform" rating in a report on Friday, March 7th. Jefferies Financial Group reissued a "buy" rating and issued a $6.00 price objective (up from $4.00) on shares of Xeris Biopharma in a research note on Wednesday, January 29th. Finally, Piper Sandler restated a "neutral" rating and set a $4.00 target price (up from $3.00) on shares of Xeris Biopharma in a research note on Friday, March 7th. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average price target of $6.10.

Insiders Place Their Bets

In related news, insider Beth Hecht sold 40,000 shares of Xeris Biopharma stock in a transaction that occurred on Thursday, March 20th. The stock was sold at an average price of $5.43, for a total value of $217,200.00. Following the transaction, the insider now directly owns 1,353,510 shares of the company's stock, valued at $7,349,559.30. The trade was a 2.87 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 6.47% of the company's stock.

Xeris Biopharma Company Profile

Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.